Late relapse in patients with diffuse large B-cell lymphoma

Julie M. Vose, Dennis D. Weisenburger, Fausto R. Loberiza, Alejandro Arevalo, Martin Bast, Joel Armitage, Philip J. Bierman, Robert G. Bociek, James O. Armitage

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


The outcomes for 162 patients with diffuse large B-cell lymphoma treated with a CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like regimen who obtained a complete remission and who subsequently relapsed after ≥5 years of remission (late relapse, N = 30), or <5 years of remission (early relapse, N = 132), were compared. The late relapsing patients had better prognostic characteristics at diagnosis, such as stage I/II disease (73% vs. 49%, P = 0.04), a normal lactic dehydrogenase (77% vs. 48%, P = 0.01), and a Karnofsky performance score of ≥80 (100% vs. 86%, P = 0.01). The 3-year survival after relapse was better in late relapsing patients (48% vs. 25%, P = 0.03), but the survival at 5 years (32% vs. 20%) and 10 years (13% vs. 14%) after relapse was not different. A multivariate analysis of factors predicting survival after relapse found age (P < 0.0001) and presence of B-symptoms (P = 0.03) to predict survival, but not early versus late relapse. A small percentage of the late relapsing patients can have a prolonged second remission. However, the overall survival from the time of relapse was not different between early and late relapsing patients with most succumbing to lymphoma.

Original languageEnglish (US)
Pages (from-to)354-358
Number of pages5
JournalBritish Journal of Haematology
Issue number4
StatePublished - Nov 2010


  • Diffuse large B-cell lymphoma (DLBC)
  • Late relapse
  • Lymphoma
  • Non-Hodgkin Lymphoma

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Late relapse in patients with diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this